Publications by authors named "Laribi K"
Purpose: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R/R DLBCL.
Methods: ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL.
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.
View Article and Find Full Text PDFUnlabelled: This phase 2 study investigated pevonedistat + azacitidine + venetoclax ( = 83) versus azacitidine + venetoclax ( = 81) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy. The study was stopped early following negative results from PANTHER, which evaluated pevonedistat in higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast AML. Outcomes were analyzed up to the datacut.
View Article and Find Full Text PDFRichter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e.
View Article and Find Full Text PDFArticle Synopsis
- Venetoclax-azacitidine is the standard treatment for unfit acute myeloid leukemia patients, but there is limited data on how long patients should continue therapy if they cannot tolerate it.
- In a study analyzing patients who stopped treatment due to poor tolerance, those who discontinued showed comparable outcomes to those who continued with azacitidine alone, with median overall survival of 44 months for newly diagnosed patients.
- The findings suggest that patients who stop treatment while in remission can have favorable outcomes, indicating a need for further controlled trials to explore optimal treatment durations.
Article Synopsis
- CD38-targeting immunotherapy combined with lenalidomide and dexamethasone is the current best standard of care for newly diagnosed multiple myeloma patients who can't undergo transplants.
- A phase 3 study involving 270 patients tested the effectiveness of adding weekly bortezomib to this regimen, comparing the outcomes of the combination (Isa-VRd) against the standard (IsaRd).
- Results showed a significantly higher rate of minimal residual disease negativity at 18 months and better response rates in the Isa-VRd group, suggesting it could become the new standard of care for these patients.
The bendamustine-rituximab (BR) schedule is an efficient first-line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression-free (PFS) and overall survival (OS). With a median follow-up of 76.
View Article and Find Full Text PDFThe real-life retrospective observational study CARMYN aimed at investigating the long-term efficacy and safety of carfilzomib in combination with dexamethasone and lenalidomide (KRd, 159 patients). These patients (62% in first and 38% in second relapse, median age 62 yo) were treated between 02/2014 and 02/2017. Most had been pre-exposed to bortezomib (98.
View Article and Find Full Text PDFArticle Synopsis
- A low allele burden (<20%) of the CALR driver mutation is present in 10.8% of patients with CALR-mutated myeloproliferative neoplasms (MPNs), primarily seen in essential thrombocythemia.
- Patients with this low allele burden tend to have a milder disease phenotype.
- Those with less than 20% allele burden also experience a slower progression of their condition compared to patients with a higher allele burden (≥20%).
Article Synopsis
- Chronic myelomonocytic leukemia (CMML) is a complex blood disorder linked to kidney issues, prompting this study to examine kidney involvement in CMML patients, their treatments, and outcomes.
- In a multicenter retrospective study involving 16 CMML patients with kidney disease, common issues included kidney injury occurring roughly six months post-CMML diagnosis, with significant findings like lysozyme nephropathy and renal infiltration.
- Despite receiving treatment, many patients faced serious kidney complications, and although kidney involvement correlated with higher monocyte counts and treatment eligibility, there was no significant difference in survival rates compared to CMML controls.
Purpose: Available tools to measure fatigue and health-related quality of life (HRQoL) in cancer patients are often difficult to use in clinical practice. The fatigue visual analogue scale (VAS) provides a simple method to assess fatigue. This study evaluated the correlation between HRQoL and fatigue perceived by cancer patients undergoing chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Patients with chronic lymphocytic leukemia (CLL) have a significantly heightened risk of developing other malignancies (OMs), with a study tracking nearly 20,000 CLL patients revealing 3,513 OMs diagnosed over 129,254 years of follow-up.
- The study found that treatment with fludarabine and cyclophosphamide increased the likelihood of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), while non-melanoma skin cancer (NMSC) and prostate cancer were common solid tumors in treated patients.
- Importantly, patients with CLL who developed OMs had lower overall survival rates, especially those diagnosed with AML and MDS, highlighting that C
Article Synopsis
- * Out of 89 participants, the treatment achieved a complete metabolic response (CMR) in 77.5% of cases after 6 cycles, with a tolerance for side effects, as 88% completed the regimen despite a 20% rate of serious adverse events.
- * In long-term follow-up (median 42 months), the 4-year progression-free survival rate was 50% and overall survival 69%, with factors like liver involvement and lymphopenia affecting outcomes.
Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or refractory multiple myeloma (RRMM). The REMIX study is one of the largest prospective, real-world analysis of the effectiveness of IXA-Rd in the setting of RRMM. Conducted in France between August 2017 and October 2019, the REMIX study, a non-interventional prospective study, included 376 patients receiving IXA-Rd in second line or later and followed for at least 24 months.
View Article and Find Full Text PDFBelantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety of BM in a real-world setting in patients who benefited from an early access program. We conducted an observational, retrospective, multicenter study.
View Article and Find Full Text PDFIn previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 trial evaluated a fixed-duration (15-month) immunochemotherapy approach in which after obinutuzumab-ibrutinib induction for 9 months, patients (n = 10) in complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) <0.01% continued only ibrutinib 420 mg/day for 6 additional months (I arm), whereas the majority (n = 115) received up to 4 cycles of fludarabine/cyclophosphamide-obinutuzumab 1000 mg alongside the ibrutinib (I-FCG arm).
View Article and Find Full Text PDFArticle Synopsis
- * A study evaluated real-world data from 389 DLBCL patients across Europe, focusing on clinical effectiveness and safety outcomes over 30 months.
- * Key findings revealed high survival rates (86% at 12 months) and a significant proportion of patients (82%) achieving a complete response to CT-P10, with adverse events aligning with typical chemotherapy effects, indicating its potential as a viable treatment option for DLBCL.
Background: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not yet approved for AML and there were therefore no formal usage recommendations. Here we report the first study in a French cohort that assessed venetoclax in combination with existing treatments for AML under real-life conditions.
View Article and Find Full Text PDFPatients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination.
View Article and Find Full Text PDFArticle Synopsis
- A study assessed the safety and efficacy of gilteritinib in 167 patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), comparing it to data from the ADMIRAL trial.
- The key differences in patient characteristics included higher rates of poor performance status and FLT3-TKD mutations, along with more complex treatment histories among participants.
- The results showed similar rates of complete remission and overall survival between treatment cohorts and highlighted the potential for outpatient treatment benefits for heavily pretreated patients.
Waldenström's disease is a B-cell neoplasm characterized by the accumulation of lymphoplasmacytic cells (LPCs) in the bone marrow, and more rarely in the lymph nodes and the spleen, which produce a monoclonal immunoglobulin M (IgM) protein. The diagnosis requires the identification of LPCs in the bone marrow, using specific markers in flow cytometry. The MYD88L265P mutation is found in 95% of cases and the CXCR4 mutation in 30-40% of cases.
View Article and Find Full Text PDFArticle Synopsis
- - The EUROPE phase 2 trial examined how well biomarkers predict the effectiveness of romiplostim (ROM) treatment for patients with lower-risk myelodysplastic neoplasms (LR-MDS) and low platelet counts, involving 77 patients from the EMSCO network.
- - Out of the participants, 42% showed significant improvements in platelet counts, lasting a median of 340 days, while other types of responses (neutrophil and erythroid) were much less common.
- - The study found that while certain mutations (like SRSF2) and baseline hemoglobin levels were linked to positive responses, ROM treatment did not affect the progression of genetic mutations in patients, confirming its safety and efficacy.
Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1) untreated adults with FLT3mut+ AML ineligible for intensive induction chemotherapy to receive gilteritinib (120 mg/d orally) and azacitidine (GIL + AZA) or azacitidine (AZA) alone. The primary end point was overall survival (OS).
View Article and Find Full Text PDF